Clinical Trial Update: Sarizotan in Parkinson Patients With L-dopa-induced Dyskinesia [Phase 2]

View source ↗

Summary

Phase 2 trial update of sarizotan for L-dopa-induced dyskinesia in Parkinson's disease; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyskinesia
• Parkinson Disease

Drugs mentioned

• Sarizotan (sarizotan)

Snippet

Sponsor: EMD Serono | Conditions: Parkinson's Disease, Dyskinesia | Phase 2 | Status: COMPLETED